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DEREGULATION of interleukin-60L-6) expression
caused the synthesis and release of many inflam-
matory mediators. It is involved in chronic
inflammation, autoimmune diseases, and
malignancy. Stephania tetrandra S. Moore is a
Chinese medicinal herb which has been used tra-
ditionary as a remedy for neuralgia and arthritis
in China. To investigate the anti-inflammatory
effects of S. tetrandra S. Moore in vitro and in
vivo, its effects on the production of IL-6 and
inflammatory mediators were analysed. When
human monocytes/macrophages stimulated with
silica were treated with 0.1-10 g/ml S. tetranda
S. Moore, the production of IL-6 was inhibited up
to 50%. At these concentrations, it had no cyto-
toxicity effect on these cells. It also suppressed
the production of IL-6 by alveolar macrophages
stimulated with silica. In addition, it inhibited the
release of superoxide anion and hydrogen
peroxide from human monocytes/macrophages.
To assess the anti-fibrosis effects of S. tetrandra
S. Moore, its effects on in vivo experimental
inflammatory models were evaluated. In the
experimental silicosis model, IL-6 activities in the
sera and in the culture supernatants of pulmon-
ary fibroblasts were also inhibited by it. In vitro
and in vivo treatment of S. tetrandra S. Moore
reduced collagen production by rat lung flbro-
blasts and lung tissue. Also, S. tetrandra S. Moore
reduced the levels of serum GOT and GPT in the
rat cirrhosis model induced by CCLl, and it was
effective in reducing hepatic fibrosis and nodular
formation. Taken together, these data indicate
that it has a potent anti-inflammatory and anti-
fibrosis effect by reducing IL-6 production.
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Introduction
Inflammation is initiated by the infiltration of
inflammatory, immune and mesenchymal cells
into the inflamed sites. Monocytes/macrophages
involved in the influx of these cells into the
inflamed site produce soluble mediators. Once
these cells have entered the inflammatory sims,
they begin to proliferate and initiate the synthe-
sizing of inflammatory and fibrogenic factors
such as collagen. The repair of tissue injury
results in replacement of the original tissue by
collagen. This collagen production not only
serves to repair the damaged tissue, but may also
cause damage to the organ.
2-4
Silicosis is an occupational lung disease result-
ing from the inhalation of silica dust which
causes chronic inflammation and progressive pul-
monary fibrosis. Inhaled silica particles are first
ingested by alveolar monocytes/macrophages,
which then release oxygen free radicals and lyso-
somal enzymes which damage lung tissue.5 They
also release pro-inflammatory cytokines which
recruit more inflammatory cells to secrete these
fibrogenic mediators inducing the proliferation of
fibroblasts and collagen synthesis.6’7 Hepatic
fibrosis is one of the chronic inflammatory liver
diseases. It is a complex process that involves the
deposition of extracellular matrix components,
activation of cells capable of producing inflam-
matory mediators, cytokines, and tissue remodel-
ling. Unbalanced production of pro-inflammatory
cytokines and inflammatory mediators has been
9 reported in chronic liver diseases.’ In cirrhotic
liver, levels of IL-1, TNF, and IL-6 are increased.
TGF-[3 is also involved in collagen synthesis and
chronic liver diseases.
As is well known, IL-6 is a regulatory factor
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which participates in the growth, differentiation
and activation of cells. It is produced and secreted
by various organ cells, and plays an important
role in defensive mechanisms of the human
body.
10 IL-6, first discovered in the culture super-
natants of monocytes, has been reported to
induce the production of antibodies by B cells.
Since the successful cloning of the cDNA of IL-
6,12 IL-6 has been reported to serve as a growth
factor for B cell hybridoma and plasmacytoma,
and as a factor participating in haematopoiesis.
4
Further, IL-6 has been reported to have the func-
tions of stimulating the activation and growth of
T cells;
15 inducing the acute phase response of
liver cells; regulating cell differentiation in the
nerve system;
17 stimulating the growth of kerati-
nocytes; regulating bone metabolism; stimulating
the growth of kidney mesangial cells; and inhibit-
ing the growth of melanoma and breast cancer
cells, etc. As has been reported, various diseases
may be the results of the improper regulation of
IL-6 production. Examples of the diseases repor-
18 19 ted are rheumatoid arthritis, hepatocirrhosis,
psoriasis,
2 multiple mveloma,
2 cardiac
myxoma,
22 AIDS23 and other autoimmune dis-
eases. These observations have buttressed the
importance of regulating IL-6 production for the
maintenance of the homeostasis of the immune
system in the human body and for the treatment
and prophylaxis of diseases.
Numerous approaches have been proposed to
regulate the production of interleukins. For
instance, proliferation of myelocytes in a patient
suffering from myeloma caused by an excessive
secretion of IL-6 has been suppressed by
emlloying antibodies against IL-6 or IL-6 recep-
tor.-24 However, no substance or method has
been reported to inhibit specifically the produc-
tion of IL-6 and, therefore, there has still existed
a need for the discovery of specific inhibitors
against the production of IL-6.
S. japonica Miers and Sinomenium acutum
Rehd et Wils (Menispermaceae), which are found
in the southern part of the Republic of Korea,
have been used for a long time as an analgesic
and anti-inflammatory agent. On the other hand,
S. tetrandra S. Moore (Menispermaceae), which
is not found in the Republic of Korea, has been
used traditionally as remedies for neuralgia and
arthritis, e.g. in China. Especially, the alkaloid tet-
randrine has been used as an anti-inflammatory
and anti-hypertensive agent. S. tetrandra S.
Moore has been reported to have anti-phagocytic
and anti-oxidizing effects, and to exhibit effec-
tiveness in clinical and experimental silicosis
25 26 models and is known to have the ability to
inhibit the production of interleukin-1 and
tumour necrosis factor-a which are secreted by
human monocytes.27’28 Tetrandrine and its deri-
vatives are reported to promote brain function
and have been developed as an antimalarial drug
and also a stimulant for hair growth.
In this study, to investigate the potent anti-
inflammatory inhibitors, extracts from the root of
S. tetrandra S. Moore were tested to suppress
the production of IL-6 and inflammatory media-
tors. It successfully inhibited IL-6 production, and
showed anti-inflammatory, anti-silicosis, and anti-
cirrhotic effects in vivo and in vitro.
Materials and methods
Isolation of extracts of S. tetrandra S. Moore..
About 4.0 kg of well dried root of S. tetrandra S.
Moore was chopped and extracted with about 51
of methanol for 2 days. The extraction procedure
was repeated three times and the combined
extracts were concentrated under a reduced
pressure to obtain about 224 g of the methanol
extract (Extract A) with a yield of 5.6%. Two
hundred grams of Extract A was partitioned with
500 ml of 90% methanol and 500 ml of n-
hexane. The 90% methanol layer was separated
and concentrated under reduced pressure to
remove methanol. The residue was adjusted to
pH 10 with 0.1 M NH4OH and partitioned with
600 ml of distilled water: CHiCl2(l:l(v/v))
mixture. The CHIC12 layer, i.e. the alkaloid frac-
tion was then separated and concentrated under
a reduced pressure to obtain about 25 g of
Extract B with a yield of 0.6%. Extract C for use
in a test for the treatment of silicosis was pre-
pared as follows. One kilogram of dried root of
S. tetrandra S. Moore was crushed into powder,
sieved (60 mesh) and then suspended in distilled
water in a concentration of 100 mg/ml. The
resulting suspension was heated at 100C for 6 h
and filtered. The filtrate was concentrated under
reduced pressure to obtain 80g of water extract
of S. tetrandra S. Moore (Extract C) with a yield
of 8%, which was then stored at-20C. For the
purpose of preparing Extract C for the treatment
of hepatocirrhosis, 1113.5g of dried root of S.
tetrandra S. Moore was introduced in a 31
round-bottomed flask equipped with a cooling
apparatus with 21 of distilled water, and the
mixture was heated at 95C for 12 h and then fil-
tered. The filtrate was concentrated under a
reduced pressure by employing a rotary vacuum
evaporator (Buchi 451), frozen in a deepfreeze
(Sanyo, Japan) at -84C for 3 h, and then lyophil-
ized for 4h by employing a lyophilizer (Eyela,
Japan) to obtain 56.55g of powdery Extract C
with a yield of 5.1%. Further, 500 g of dried root
of S. tetrandra S. Moore was extracted with
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about 1.51 of ethanol at room temperature for 3 mg/ml, BM, Indianapolis, IN, USA) and DNase
days. The extraction procedure was repeated type I (0.15 mg/ml, Sigma), and incubated at
three times and the combined extracts were con- 37C for 2 h in a 5% CO2 incubator. Then, 0.5%
centrated under reduced pressure to obtain 13 g trypsin-0.2% EDTA was added and the incubation
of ethanol extract of S. tetrandra S. Moore with was continued for 30 min. The digested tissue
a yield of 2.6% (Extract D). was washed twice with PBS and once with
DMEM, and isolated cells were suspended in
Cell culture: DMEM containing 10% FBS (DMEM-10% FBS)
(1) Separation of human monocytes/macro- and incubated for 1 week. Thereafter, synovial
phages. Heparinized normal human peripheral adherent cells were isolated with trypsin-EDTA,
blood was diluted with an equal amount of washed with DMEM and then suspended in
Hank’s balanced salt solution (HBSS: Ca
2+ and DMEM-5% FBS in a concentration of 105 cells/
Mg
2+ free). The diluted blood was put into a ml.
centrifuge tube containing two layers of Ficoll- (4) Treatment of cells with extracts ofS. tetra-.
Hypaque (Sigma, St Louis, MO, USA), one with a ndra S. Moore. Extracts of S. tetrandra S. Moore
density of 1.077 and other with a density of were added in various concentrations to 1-5 x
1.119, and then centrifuged at 700 x g for 30 105/ml of cells which were obtained in the above
min to obtain monocytes from the layer between procedures, and the cells were preincubated at
Ficoll-Hypaque layer with a density of 1.077 and 37C for l h in 5% CO2 incubator. Then, l ml
serum layer. The separated cells were washed each of silica (100 g/ml) and RPMI 1640
twice with 4C HBSS (Ca
2+ and Mg
2+ free) and medium containing 2% FBS were added and the
resuspended in RPMI 1640 medium (Gibco, cells were cultured under the same conditions as
Grand Island, NY, USA) containing 10% foetal above for 48 h. The culture supernatant was col-
bovine serum (FBS, Hyclone, Logan, UT, USA). lected and centrifuged at 1 500 rpm for 10 min to
The suspensions were added to the wells of a remove the cells and silica. The obtained super-
24-well incubation plate (Costar, Cambridge, MA, natant was dialyzed against PBS and filtered by
USA) and incubated at 37C for 2h to obtain 0.2 l.tm filtration syringe, and the filtrate was
monocytes/macrophages, stored at-20C.
(2) Separation of alveolar macrophages. Rat
alveolar macrophages were obtained by broncho- Assay for cytotoxicities of Extracts of S. tetrandra
alveolar lavage.29 Rats were anaesthetized with S. Moore. The cytotoxicities of the extracts of S.
ketamine and their alveolar macrophage were tetrandra S. Moore were determined by the fol-
obtained therefrom by inserting a sterilized thin lowing procedures. Briefly, 5 x 105 cells/ml
tube into the bronchia and repeating three times each of monocytes and macrophages were
the injection of 10 ml of RPMI 1640 medium treated with 0.1, 1 and 10 l.tg/ml each of Extracts
with a 30 ml syringe. The obtained cells were A and B obtained as described above and incu-
centrifuged at 400 x g for 5 min, suspended in bated under the same conditions. In accordance
50 ml of RPMI 1640 medium containing 10% FBS with the method of Alley et aL, the culture was
and then incubated at 37C for 2h to adhere to added to the wells of the incubation plate, and
the incubation plate. The plate was washed twice 100 btg of 3-4,5-dimethylthiazol-2,5-diphenyl-tet-
with washing buffer (PBS) to remove alveolar razolium bromide (MTT, Sigma)was added to
lymphocytes (floating cells) and to obtain alveo- each of the wells. After incubating at 37C for
lar macrophages. 4 h, the culture was centrifuged to remove super-
The alveolar macrophages (2 x 105 cells/ natant. One hundred each of acidified iso-
well) were added to the wells of a 24-well incu- propanol (0.04 N HCl in isopropanol) was added
bation plate and treated with 100 l.tg/ml of silica to the cells in each well to elute formazan pro-
and 10 gg/ml of Extract A for 3 days. The culture duced by the living cells, and optical density
was centrifuged to obtain the culture super- (O.D.) was determined at 540 nm by using an
natants, which were then dialyzed against PBS. ELISA reader (Titertek multiskan Mcc/340).
The activity of IL-6 was determined using an IL-6
dependent B9.55 hybridoma cell line. Cytokine assay.. TNF-z activity was measured by
(3) Separation of synoviocytes from patients cytolysis of TNF-0t sensitive murine fibroblast cell
with rheumatoid arthritis. Synovial membrane line, L929 cells (ATCC, CCL 1, NCTC clone 929).
tissue of a patient suffering from rheumatoid In brief, 3 x 10
4 L929 cells were plated on a 96-
arthritis was washed three times with cool PBS well tissue culture plate. After 24h incubation,
and cut into small pieces, which was then sus- media were removed and various dilutions of
pended in Dulbecco’s Modified Eagle’s Medium samples or various concentrations of recombi-
(DMEM; Sigma, USA) containing col!agenase A (5 nant human TNF-cz (Genzyme, Cambridge, MA;
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specific activity 2 x 107 U/mg) were added in tion (4M guanidinium thiocyanate, 25 mM
duplicate to each well containing 1 btg/ml (final sodium citrate, pH 7.0, 0.1 M 2-mercapto-ethanol,
concentration) of actinomycin D (Sigma)and 5% 0.5% sarcosine) to obtain RNA. To synthesize a
FBS. After 18h incubation at 37C, media were single-strand cDNA from the RNA obtained
removed and cells were washed three times and above, a reverse transcription reaction was
stained with 0.5% crystal violet solution contain- carried out by employing M-MLV reverse tran-
ing 20% methanol. After washing off the excess scriptase (Promega, USA). Then, a polymerase
dye, the plates were dried and 33% (v/v) acetic chain reaction (PCR) was carried out to amplify
acid was added to each well (100 I.tl/well) and cDNA. Twenty l.tl of reverse transcription reac-
the optical density at 570 nm was measured with tion, 8 l.tl of 10 x PCR buffer (100 mM Tris-HCl,
an ELISA reader. TNF activity was expressed as pH 8.3, 400 mM KC1, 120 mM DTT, 15 mM
U/ml from the extrapolation of the standard MgCl2, 5 btg/ml BSA), 1 l.tl (20 pmol) of 5’-end
curve obtained using recombinant human TNF-a primer (5’-ATGAACTCCTTCTCCACAAGCGC-3’),
(Genzyme). The activity of IL-6 was determined 1 !1 (20 pmol) of 3’-end primer (5’-GAAGAG-
by using an IL-6 dependent B9.55 hybridoma cell CCCTCAGGCTGG-ACTG-3’), 69 l.tl of distilled
line. B9.55 cells were cultured in RPMI 1640 water and 1 I.tl (2.5 U)of Taq DNA polymerase
medium containing 10% FBS with the addition of (Promega, USA) were mixed well and the
2 U/ml of recombinant human IL-6, and the cells mixture was incubated at 95C for 5 min. The
were washed three times with serum-free PCR was carried out by repeating 30 times the
medium. The cells were suspended in RPMI 1640 thermal cycle consisting of 95C for 1.5 min;
medium containing 10% FBS in a concentration 55C for 1 min; 72C for 1.5 min, and the reac-
of 5 X 10
4 cells/ml, and the suspension was tion mixture as consequently incubated at 95C
added to the wells of a 96-well incubation plate for 1.5 min; at 55C for 1 min; and at 72C for 5
in an amount of 100 btl/well. Then the plate was min. Ten of the PCR product was subjected to
incubated at 37C under 5% CO2 for 68 h. an electrophoresis on an 1.0% agarose gel at 100
[H]thymidine (0.5 Ci)was added to the wells volts for 30 min. The gel was stained in EtBr
in the amount of 50 l.tl/well and incubation was solution for 10 min, washed with distilled water
continued for 4h. When the incubation was and photographed.
completed, the cells were collected on a glass
fibre filter by using a multiple cell harvester IL-6 CAT assay.. The plasmid IL-6-CAT was con-
(Inotech) and the amount of incorporated structed by fusing IL-6 promoter (from-1180 to
[3H}thymidine was determined by a liquid scintil- + 13) and the bacterial CAT transcription unit.31
lation counter (Beckman, Somerset, NJ, USA). On the day before DNA transfection, HeLa cells
IL-6 ELISA was performed using IL-6-specific were plated at a density of 5 x 105 cells per 60
monoclonal and polyclonal antibodies obtained mm Petri dishes in DMEM supplemented with
from Genzyme (Cambridge, MA). IL-1 activity was 5% FBS. On day 2, 3 h before transfection, fresh
determined using thymocyte costimulation assay DMEM containing 1% FBS was added and cells
as described. Briefly, thymocytes were prepared were transfected by the calcium phosphate-DNA
from female CH/HeJ mice and resuspended in co-precipitation method with a total of 8 btg of IL-
RPMI containing 10% FBS and 2 t.tg/ml phytohae- 6-CAT DNA. After 18h, cells were washed with
magglutinin. 1 x 10 cells (100 tl) were plated serum-free medium and added with fresh DMEM
on a 96-well tissue culture plate and various dilu- containing 1% FBS. Then cells were further incu-
tions of samples (100 btl) were added to each bated for 18h in the presence of 10 l.tg/ml of
well. After 44h incubation, cells were labelled LPS plus 100 ng/ml of PMA and/or 10 l.tg/ml of
with 0.5 l.tCi/well [3H]thymidine for 4h. One unit EXT.B. The cell extracts were heat-inactivated at
of cytokine was defined as the amount inducing 65C for 10 min and centrifuged and assayed at
the half maximal proliferation. 37C for 2h with the equal amounts of protein
(20 l.tg) as measured by using Bio-Rad protein
assay kit. The CAT expression was detected by
IL-6 gene expression.. The synoviocytes (1.5 x TLC and autoradiography.
10 cells/well) were incubated at 37C under 5%
CO. for 24h until it adhered to the wells. One Collagen synthesis: Collagen released from the
tg/ml or 10 l.tg/ml of Extract B was added to the fibroblast cells was measured by indirect ELISA
wells and the plate was incubated at 37C under using anti-type I collagen antibody (Southern
5% CO2 for I h and stimulated with 100 btg/ml Biotechnology). Collagen synthesized in the lung
silica for 12h. Then, the culture medium was tissue of the rats was assayed by measuring the
removed, and the cells were washed with PBS, amount of hydroxy proline.2 To measure the
disrupted by adding 500 1 of denaturating solu- amount of synthesized collagen by rat pulmonary
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fibroblasts, collagen (Sigma, type I) as an internal
control group was dissolved thoroughly in 1M
acetic acid containing 1 mg/ml of pepsin, and
the solution was serially diluted 5-fold with
coating buffer (0.05 M carbonate, pH 9.6) in a
concentration ranging from 1 g to 16 pg. The
diluted solutions were added to the wells of a
fiat-bottomed microtiter plate (Dynatech, Cantilly,
VA, USA, Immulon 2) in the amount of 100 tl/
well. In addition, 1 ml of the culture supernatants
of rat pulmonary fibroblast were concentrated up
to 10- to 20-fold using a speedvac dryer (Savant,
Hicksville, NY, USA) and dissolved in 100 btl of
coating buffer (0.1 M NaHCO3, 0.02% NAN3; pH
was adjusted to 9.6 with NaiCO), and the solu-
tion was added to the wells in an amount of 100
btl/well and then incubated at 4C overnight. The
plate was washed three times with washing
buffer (PBS, 0.05% Tween 20, pH 7.4), and 2%
bovine serum albumin (BSA, Sigma) was added
to the wells in an amount of 100 l.tl/well. The
plate was incubated at room temperature for 2 h
to block the uncoated parts. The plate was
washed four times with the same buffer as
above, and alkaline phosphatase-conjugated
rabbit anti-goat IgG (Cappel, Dunham, NC, USA)
which was 1 000-fold diluted with a dilution
buffer (0.05 M Tris-HCl, 1 mM MgCli.6H20,
0.15 M NaC1, 0.02% NAN,, 1% BSA, 0.05% Tween
20, pH 8.1) was added to the wells in an amount
of 100 Il/well. The plate was incubated at 37C
for 2h and then washed three times with the
same buffer. To the wells was added 100 l.tl/well
of /nitrophenyl phosphate which was diluted
with substrate buffer (0.05 M NaHCO, 10 mM
MgCl2"6H20, pH 9.8) in a concentration of 1
mg/ml, and the O.D. was determined using an
ELISA reader at 405 nm. The amount of pro-
duced collagen was calculated from the O.D.
value with reference to that of the internal
control group.
Production of reactive oxygen species: The
amount of H202 was determined by a microassay
employing a 96-well microplate as follows. 5 x
10 cells of human monocytes/macrophages
were added to each well containing RPMI 1640
medium, and 25 btl of horseradish peroxidase
(500 tg/ml; type II, Sigma) and 75 btl of phenol
red (1 mg/ml) were added to each of the wells.
Thereafter, the cells were treated with 10 l.tg/ml
of Extract A for i h, stimulated with 100 t.tg/ml
silica and then reacted at 37C for 60 min. When
the incubation was completed, 3M NaOH was
added to the wells in an amount of 25 t.tl/well to
stop the reaction and O.D. was measured at 620
nm by using an ELISA reader. The amount of
H202 was determined by employing a standard
curve prepared using the diluted standard H202
(Sigma).
For the purpose of measuring the amount of
produced O2-, monocytes/macrophages sus-
pended in RPMI 1640 medium in a concentration
of 1 x 10 cells/800 btl was added to the wells
of a 24-well plate, and 10 l.tg/ml of superoxide
dismutase (SOD, Sigma) was added to the empty
wells. The plate was stored at 37C for 2 min, and
cytochrome C (3 mg/ml, Sigma) was added to
the wells in a concentration of 100 l.d/well. The
cells were treated with 10 l.tg/ml of Extract A for
i h, and stimulated at 37C for 20 min by adding
100 l.tg/ml silica. The reaction was terminated by
adding 1 mM N-ethylmaleimide (Sigma) to the
wells and the culture was centrifuged at 1600 x
g for 10 min to obtain the supernatants. The
change of color caused by the reduction of cyto-
chrome C was measured at 550 nm using an UV-
visible spectrophotometer (Kontron Instrument,
Milan, Italy). The amount of produced O2-was
represented by the concentration of SOD which
can suppress the reduction of cytochrome C in 1
x 10 cells for 20 min, by employing the extinc-
tion coefficient of cytochrome C (E550nm 1.83
x 10
4 mM-
cm-1).
Experimental silicosis and cirrhosis model.. To
induce the experimental hepatocirrhosis in 4-
week aged male Sprague-Dawley rats, 0.1 ml/
100 g of body weight of CC14 solution (50% CC14
+ 50% corn oil)was injected intraperitoneally to
the rats twice a week, and 0.2 ml each of Extract
A, B, C or D was administered orally at the time
of the injections of CC14 twice a week. After 13
weeks, each of the rats was anaesthetized with
ether and blood samples were obtained from the
heart to determine the levels of serum glutamic-
oxaloacetic transaminase (sGOT) and serum glu-
tamic-pyruvic transaminase (sGPT).
For the pathohistological examination of the
livers separated from the rats, the liver was fixed
in 10% aqueous solution of neutral formalin and
then embedded in paraffin. The embedded tissue
was sectioned into 5 mm slices, stained with hae-
matoxylin eosin and Masson’s trichrome, and
then observed under the microscope.
Results
Cytotoxicity of extracts of S. tetrandra $. Moore..
The cytotoxicity of the extracts of S. tetrandra S.
Moore were determined as described Materials
and Methods. Figure 1 shows the relative values
of optical density of the sample with respect to
the concentration of Extract A or B when the
optical density of the control group which was
not treated with Extract A or B is regarded as
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FIG. 1. Cytotoxicity of S. tetrandra S. Moore on human mono-
cytes/macrophages. Human monocytes/macrophages (1 x 105
cells/well) were isolated and incubated with various concentra-
tions of S. tetrandra S. Moore (Extract A or B) for 48 h at 37C.
Then the cells were further incubated with 0.5 mg/ml of 3-4,5-
dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) for 4h.
The cells were pelleted and resuspended in 100 !1 of acidified
prophylalcohol. The samples were mixed with 20 I1 of 3% SDS
and read on an ELISA reader at 540 nm. Data represent the
standard deviation (SD) of five different determinants.
100%. The samples treated with Extract A show
no difference from the control group until the
concentration of Extract A reaches 10 l.tg/ml, and
the samples treated with Extract B show similar
results. Therefore, it indicated that Extracts A and
B had no cytotoxicity at concentrations lower
than 10 l.tg/ml, therefore, hereinafter, all the tests
were carried out within this concentration. Both
Extracts A and B showed cytotoxicity at the con-
centration of 100 l.tg/ml. In vivo oral treatment
of Extracts C and D showed no apparent toxicity
to the rats (death, loss of weight, etc.)when it
was administered twice a week for 17 weeks
(data not shown).
Inhibition oflL-dproduction by extracts ofS. tet-
randra S. Moore: Human monocytes/macro-
phages were incubated with 0.1 to 10 Ig/ml of
Extract A or B for i h and treated with 100 l.tg/ml
of silica for 48 h. The culture was centrifuged to
obtain the culture supernatants, which were then
dialysed against PBS. IL-6 production was mea-
sured by IL-6 bioassay using B9.55 cell line.
Figure 2A shows the relative values of the
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FIG. 2. Inhibitory effects of extracts of S. tetrandra S. Moore on IL-6 production. (A) Human monocytes/macrophages (1 x 105/well)
were incubated with various concentrations of S. tetrandra S. Moore for h and stimulated with 100 lg/ml silica. After 48 h incuba-
tion, the culture supernatants were collected, centrifuged, dialysed, and filtered to remove the extracts. IL-6 production was bioassayed
as described in Materials and Methods (control, silica only; 32 U/ml IL-6). (B) Rat alveolar macrophages (1 x 106 cells/well) were
incubated with 10 Ig/ml S. tetrandra S. Moore for h, stimulated with silica, and assayed for IL-6 as described in (A) (control, silica
0nly; 28 U/ml). Data show the mean -t- SD of three different determinants (-, p < 0.05). (C) The culture supernatants of human
monocytes/macrophages (C. Sup) or of rat alveolar macrophages (A. Mo) treated with 10 Ig/ml PWM and 10 Ig/ml extracts were
analysed for IL-6 concentration using IL-6 ELISA. (D) The experimental .silicosis was induced as described in Materials and Methods.
Then, Extract C (40 mg/injection) was administered orally, or murine IL-6 polyclonal antibody (250 lg/injection) was injected intrave-
nously, into the silicosis rats twice per week for 17 weeks. IL-6 activities in the sara were determined as described in Materials and
Methods. (E) The culture supernatants of pulmonary fibroblasts isolated from silicosis rats (D) were analysed for IL-6 activity.
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amount of incorporated [H]thymidine with
respect to the concentration of Extract A or B
compared with those of the control group. IL-6
production by monocyte/macrophage was inhib-
ited by Extract A or B in a dose-dependent
mode, and it was inhibited by 50% with 10 btg/ml
of Extract A or B. As shown in Fig. 2B, it was
observed that the IL-6 production by rat alveolar
macrophages was also inhibited by Extract A. As
blank controls for possible residual effects of
compounds and silica on bioassay, the same
concentrations of compounds and silica were
mixed with fresh media and dialysed as the
culture supernatants were prepared. These blank
controls had no effects on bioassay (data not
shown). The results of IL-6 bioassay were further
confirmed by IL-6 ELISA (Fig. 2C). In this case,
cells were treated with 10 txg/ml pokeweed
mitogen (PWM) and 10 l.tg/ml extracts. Extract A
and B showed dramatic inhibitory effects on IL-6
production. Next, the effects of S. tetrandra S.
Moore on IL-6 production in vivo were analysed.
In the experimental silicosis model, IL-6 activities
in the serum (Fig. 2D) and in the culture super-
natants of pulmonary fibroblasts isolated from
the rats treated with compounds or anti-murine
IL-6 monoclonal antibody (Fig. 2E) were deter-
mined as described in Materials and Methods. IL-
6 activity was inhibited by injecting anti-IL-6 anti-
body as expected. And its activity was also inhib-
ited by Extract C in both cases, indicating that
the extracts of S. tetrandra S. Moore exhibited
the inhibitory effects on IL-6 production in the
animal silicosis models.
Suppression of IL-6 gene expression by extracts
ofS. tetrandra S. Moore.. In addition, to confirm
the effects of the extracts of S. tetrandra S.
Moore on the IL-6 gene expression, the effect of
Extract B on synoviocytes which were obtained
from the patients with rheumatoid arthritis
caused by the overproduction of IL-6s was ana-
lysed. As can be seen in Fig. 3A, the expression
of constantly expressed adenine phosphoribosyl
transferase (APRT) RNA was not influenced by
Extract B, while IL-6 RNA expression was sig-
nificantl inhibited by 10 g/ml of the Extract B.
When IL-6-CAT construcff" was used to see the
effects of Extract B on IL-6 promoter activity, the
IL-6 promoter activity induced by LPS plus PMA
was suppressed about 60% by 10 l.tg/ml of the
Extract B. However, acanthoic acid (A), another
natural product which had no effect on IL-6 pro-
duction,34 did not inhibit the IL-6 expression
(Fig. 3B,C). These results indicated that the
extracts of S. tetrandra S. Moore suppressed IL-6
production at the transcriptional level, and
further studies are required to know the exact
A
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FIG. 3. Suppression of IL-6 gene expression by Extract B. (A)
pg/ml or 10 lg/ml of Extract B was added to the synoviocytes
of patients with rheumatoid arthritis (1.5 x 106 cells/well) and
was incubated at 37C, 5% CO2 for h and treated with 100
Ig/ml silica for 12h. RNA were prepared, and IL-6 or APRT
gene expression was measured by RT-PCR using specific primers
as described in Materials and Methods. (B) 8 lg of IL-6-CAT con-
struct was transfected into HeLa cells by the calcium phosphate-
DNA coprecipitation method. The cells were incubated in DMEM
containing 1% FBS for 18 h. Cells were then treated with 10
ml LPS plus 100 ng/ml PMA (LP), 10 lg/ml EXT.B, or 10 pg/ml
acanthoic acid (A) for 18 h. The CAT expression was measured
as described in Materials and Methods. (C) The CATactivity was
calculated as follows: percentage acetylated (cpm in acety-
lated species)/(cpm in acetylated species + cpm in non-
acetylated chloramphenicol).
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suppressive mechanism of S. tetrandra S. Moore
on IL-6 gene expression.
Inhibition of silicosis by extracts ofS. tetrandra $.
Moore.. IL-6 is known as a cytokine which causes
fibrogenesis and induces collagen synthesis in rat
fibroblasts.5 Based on the observation of the
inhibitory effects on the IL-6 production, their
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FIG. 4. Inhibition of collagen synthesis by extracts of S. tetrandra
S. Moore. (A) Primary rat lung fibroblasts (5 x 106 cells/well)
were preincubated with 10 ig/ml Extract A for h and stimu-
lated with 100 lg/ml silica. After 48h incubation, the culture
supernatants were assayed for collagen production by ELISA
using anti-collagen type antibody. (B) The experimental silicosis
was induced as described in Materials and Methods. Then,
Extract C (40 mg/injection) was orally injected into the silicosis
rat twice per week for 17 weeks. The lung tissue (0.1 g) was
hydrolyzed and assayed for collagen content by measuring
hydroxy proline. Data represent the percentages of control
(normal lung).
inhibitory effect on the collagen synthesis in rat
pulmonary fibroblasts and pulmonary tissues was
determined. As a result, it was observed that the
amount of synthesized collagen was significantly
decreased in the culture supernatants of rat pul-
monary fibroblasts which were treated with 10
g/ml of Extract A compared with the control
(Fig. 4A). Furthermore, in vivo effects of S. tetra-
ndra S. Moore (Extract C) on the collagen
synthesis in rat pulmonary tissues was tested by
injecting 500 mg of silica and 40 mg of Extract C
orally into the rats twice a week for 17 weeks,
and then the amount of hydroxyproline was
measured as described in Materials and Methods.
In Fig. 4B, the amount of collagen synthesized by
rat pulmonary tissues from the rats treated with
silica only (si) or treated with silica and dimethyl-
sulphoxide (si+DMSO) increased about twice
compared with the control, while the amount of
synthesized collagen decreased by 50% in rat
pulmonary tissue treamd with silica, DMSO and
Extract C (si+ EXT.C). These results showed that
the extracts of S. tetrandra S. Moore had anti-
fibrogenic activity in vitro and in vivo.
Inflammatory responses are known as a
cascade reaction comprising the secretion of
various cytokines such as IL-1, IL-6, and TNF-a
--" 120
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FIG. 5. Inhibition of production of reactive oxygen species by
extract of S. tetrandra S. Moore. For hydrogen peroxide analysis,
human monocytes/macrophages (5 x 10s cells/ml) pretreated
with 10 lg/ml Extract A for h were stimulated with 100 lg/
ml silica for h in the presence of horseradish peroxidase and
phenol red. For superoxide anion analysis, human monocytes/
macrophages (1 x 106 cells/800 IJ) pretreated with 10 lg/ml
Extract A were stimulated with 100 Ig/ml silica for 20 min in
the presence of cytochrome C. I-1, superoxide anion; ,, hydro-
gen peroxide.
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from immune cells stimulated by various stimu-
lants; production of phospholipase A2, lysosomal
enzyme, reactive oxygen species, etc. by other
immune cells stimulated by various cytokines;
and damage of tissues induced by the inflamma-
tory mediators. The ability of the extracts of S.
tetrandra S. Moore to block the inflammatory
reactions was tested by measuring their inhibi-
tory activity to the production of reactive oxygen
species such as H202 and 02-. As can be seen
from Fig. 5, the amounts of H202 and O2-
decreased significantly in the silica-stimulated and
Extract A-treated monocytes/macrophage
(si+ EXT.A) in contrast with the control group
treated with only silica (si+ MED).
Inhibition of hepatocirrhosis by extracts of S. tet-
randra S. Moore: Cirrhosis is another fibrotic
disease in the liver. Anti-inflammatory effects of S.
tetrandra S. Moore were analysed in the experi-
mental cirrhosis model. When compared with the
blood sample obtained from the rats treated with
CC14, DMSO, and PBS, sGOT values of the blood
samples obtained from the rats treated with
Extract A or C did not decrease, but those of
samples obtained from the rat treated with
Extract D or B decreased by 20% and 40%,
respectively (Fig. 6A). Further, sGPT in the blood
samples obtained from the rats treated with
Extract B decreased more than 60% (Fig. 6B).
In the liver of the rats administered with CC14
only (Fig. 7B), the nodule formation of hepatic
lobules with the thickened fibrous bands was
remarkable compared with the normal liver (Fig.
7A). In the liver of the rats administered with
CC14 and Extract B (Fig. 7D), the fibrous bands
surrounding the nodule of hepatic lobule were
thinner than those of the liver obtained from the
rats treated with CC14 only, and many nodules
were incomplete. Also, the regenerative change
of hepatic cells decreased compared with that of
the liver obtained from the rats treated with CC14
only. In the liver of the rats administered with
CC14 and Extract A (Fig. 7C), the suppressive
effect on the hepatocirrhosis was not dominant
as seen in the case of Extract B.
Discussion
Inflammation is a localized or systemic
response induced by infection or injury to
tissues. Right after exposure to injurious agents,
monocytes and macrophages synthesize and
release a variety of inflammatory mediators such
as oxygen free radicals, proteases, platelet-activat-
ing factors, and proinflammatory cytokines.’2
They are major inflammatory mediators that
modulate fibroblast proliferation, neutrophil
function, and collagen synthesis. Once macro-
phages infiltrated into inflammatory sites,
NADPH-oxidase in the membrane is activated to
produce the oxygens. The oxygens are then
reduced to superoxide anion by receiving an
electron from NADPH, and then dismutated to
hydrogen peroxide. These reaction oxygens then
damage the tissues in the inflammatory sites.
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FIG. 6. Effects of Extracts of S. tetrandra S. Moore on serum GOT and GPT of cirrhotic rats. The experimental cirrhosis was induced by
CCI4 as described in Materials and Methods. Then, 40 mg each of Extract A, B, C, D was orally injected into the cirrhotic rats for 13
weeks. The sera were obtained and analyzed for GOT and GPT (--, p < 0.01" r, P < 0.05).
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FIG. 7. Extracts of S. tetrandra S. Moore suppressed the experimental cirrhosis. 40 mg each of Extract A, B was injected into cirrhotic
rats for 13 weeks. The liver was fixed, stained with Masson’s trichrome stain for histological analysis. (A) normal liver, (B) CCI4, (C)
CCI4 and Extract A, (D) CCI4 and Extract B. Data shown the mean ___
SD of three different determinants.
Therefore, an excessive quantity of these cyto-
kines and free radicals caused tissue destruction
in the inflammatory sites and they are involved in
many immune diseases and inflammatory dis-
eases. To inhibit their action, several protein
antagonists such as IL-lra, monoclonal antibodies
to proinflammatory cytokines, and these cytokine
receptors have been developed to block acute
and chronic inflammation. But these protein
antagonists have some limitations such as stability
and delivery to be used clinically as anti-inflam-
matory agents.
Two major aspects of the proliferation of
fibroblasts and the production of collagen are
the hallmarks of fibrosis. IL-6 has been known to
be involved in this process in connection with
other fibrogenic cytokines. To modulate IL-6 pro-
duction, S. tetrandra S. Moore, known as anti-
inflammatory agent, was tested in different
inflammatory systems. First, several aspects of IL-
6 in chronic inflammation including silicosis,
rheumatoid arthritis, and liver cirrhosis were eval-
uated. Significantly elevated levels of IL-6 activity
were observed in silica-treated monocytes/macro-
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phages, and in the sera of CCl4-treated rats and
the patients with rheumatoid arthritis, indicating
that .L-6 is a key element in an inflammatory
cytokine network. The culture supernatants of
human monocytes/macrophages treated with S.
tetrandra S. Moore contained far less IL-6 activity
compared with those treated with silica alone. In
addition, it suppressed the IL-6 gene expression,
collagen synthesis, and the production of reactive
oxygen from several inflammatory cells, suggest-
ing that it had potent anti-fibrogenic effects. But
it cannot be ruled out that S. tetrandra S. Moore
may regulate the production of other proin-
flammator cytokines. Actually, Extract B of S. tet-
randra S. Moore showed the inhibitory effects
on IL-1 production (29.1% and 45% inhibition at
the concentration of 1 I.tg/ml and 10 btg/ml,
respectively) and on TNF<z production (5.2%
and 18.6% inhibition at the concentration of 1
I.tg/ml and 10 l.tg/ml, respectively). The further
fractionation of the extracts to identify the effec-
tive components inhibiting each cytokine pro-
duction is now in progress.
To evaluate the in vivo effects of S. tetrandra
S. Moore, two different experimental models, in
which IL-6 is known to be involved, were tested.
Silicosis is a chronic lung inflammation. By the
exposure to stimuli, alveolar macrophages are
activated and secrete many fibrogenic mediators.
S. tetrandra S. Moore strongly suppressed the
experimental silicosis induced by silica treatment.
It reduced the collagen production, and granu-
loma formation and fibrosis in the lung.
Hepatocirrhosis is characterized by the fibro-
genesis of the whole liver, complete disruption
of liver parenchyma by the fibrous septa, and
formation of regenerative nodules. It is derived
mostly from a chronic hepatitis or chronic alco-
holism, however, the precise causes are
unknown. We previously reported that in vivo
administration of IL-6 could induce the early
stage of liver cirrhosis.7 In a hepatocirrhosis
patient, the amount of cytokines, e.g. IL-6 which
is involved in the inflammation and fibrogenesis,
is in an increased state. Based on its effects on
IL-6 production, these inhibitory effects in vivo
might be due to reduction of IL-6 and/or other
inflammatory mediators induced by IL-6 such as
reactive oxygens free radicals.
Various root extracts of S. tetrandra S. Moore
which inhibit the production of interleukin-6, can
be used for the preparation thereof and pharma-
ceutical compositions comprising extracts which
are effective for the treatment of immune dis-
eases caused by the overproduction of inter-
leukin-6. Each of Extracts A, B, C and D
exhibited an anti-inflammatory effect, inhibited
the synthesis of collagen and the production of
the reactive oxygen species and reduced GOT
and GPT level in the serum. Therefore, they can
be employed alone or in combination with each
other in a pharmaceutical composition for the
treatment of such immune diseases caused by an
excessive production of IL-6 as rheumatoid
arthritis, hepatocirrhosis, psoriasis, multiple
myeloma, cardiac myxoma, and silicosis. These
extracts seemed to have the similar effects on IL-
6 production, but they showed some different
effects on experimental animal models. The
Extract B was most effective in suppressing
serum GOT and GPT level, and hepatic cirrhosis.
Preferably the Extract B may be applied for the
treatment of inflammatory disease, arthritis and
autoimmune hepatocirrhosis, but the subsequent
studies are required to identify the active com-
pounds as mentioned above.
In summary, significantly elevated levels of IL-6
activity and concentration were observed in
silica-treated human monocytes/macrophages,
CC14-or silica-treated rats, and the patients with
rheumatoid arthritis. In addition, IL-6 itself aug-
mented fibrogenic events such as fibroblast or
synoviocyte proliferation, and collagen synthesis.
S. tetrandra S. Moore possesses the. ability to
inhibit the production of IL-6 and inflammatory
mediators in a concentration-dependent fashion.
It was also effective in experimental silicosis and
cirrhosis models. Considering its effects on cyto-
kine regulation and in vivo effects, it can be
used as an anti-fibrosis agent in the treatment of
many inflammatory diseases. Further biological
and immunological analysis of its isolated com-
pounds can lead to the development of more
specific anti-inflammatory therapeutics for the
treatment of various immune diseases caused by
an excessive production of IL-6 and other inflam-
matory mediators.
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